Antipsychotics are an important therapeutic option for many individuals with schizophrenia and other psychoses, as well as for several other non psychotic mentally disordered. The beneficial effects of atypical antipsychotics on positive symptoms, negative symptoms, and cognition in schizophrenia, as well as the reduced rate of extra-pyramidal effects have led to the wide use of these drugs in clinical practice 1, 2 . However, their administration might lead to a marked increase in body weight in ,
INTRODUCTION:
addition to metabolic abnormalities [3] [4] [5] [6] [7] [8] [9] . Obesity in addition to be a growing problem in the general population worldwide, presents at even greater rates among schizophrenic patients 10, 11 . Many factors contribute 12 , including lack of exercise 13 , lack of adequate medical care 14 , and a possible predisposition toward weight gain in general 15 , or in association with improvement of symptoms 5, 16 . Weight gain associated with antipsychotic treatment has been commonly reported 2, 17 . Antipsychotic-drug induced weight gain has a number of meaningful clinical implications, particularly in the long-term management of schizophrenia. In addition to its effect on general health risks, weight gain has a major impact on the subjective acceptance of these drugs and thereby on adherence to the medications 18 . Substantial body weight gain occurs in up to 50% of patients during long-term antipsychotic treatment 19 . Second-generation antipsychotics can cause large increases in body weight; clozapine and olanzapine appear to cause the most weight gain, risperidone is associated with intermediate weight gain, and ziprasidone is associated with less weight gain than haloperidol 3, 20, 21 . Objectives: the main objective of the study was to compare the evidence of weight gain, as a side effect, between those who treated with Olanzapine and those who treated with Risperidone. Moreover, the author tried to find out the effect of gender for such a side effect within each group.
A one year retrospective study was performed by reviewing charts of patients at Hawler Teaching Hospital, both psychiatric out-patient and in-patient units, in Erbil city, who were treated between April 2008 and April 2009, comparing the baseline weight in kilograms with after one month (30 ± 5 days) weight in those who treated with either Olanzapine or Risperidone. Data were analyzed by gender differences. Inclusion criteria: Included for analysis were patients treated with either Olanzapine or Risperidone alone (mono-therapy), with baseline weight records (before starting therapy) in kilograms, and only those who have been followed for their weight changes by the same weight scale measure. The last criterion included to avoid different raters variability among the scale measures.1017 patient charts have been reviewed by the author, only 80 patient charts fulfilled the inclusion criteria, 60 were treated with Olanzapine (2.5 to 20 milligrams daily) and the remaining 20 patients were treated with Risperidone (1 to 6
MATERIALS AND METHODS:
milligrams daily). Whole the weight measurements of the 80 patients were carried out by the author and by using the same weight measure instrument of the psychiatric unit mentioned above. Statistical Analyses: The mean differences between Olanzapine-treated group and Risperidone-treated group, and the mean differences between baseline weight and after one month therapy weight within each group were measured by adopting Student t-tests, unpaired and paired tests relatively, all 2 tailed, with both equal and unequal variances accordingly. For the measurement of variances equality, F-test Two Sample for Variances was adopted. For the paired t-tests, and for purpose of more accurate and complete understanding of the results, 95% Confidence Interval (CI) of the amount of weight gain has been measured to determine the amount of weight change around the mean weight change after one month of therapy. In an attempt to assess the differences in the numbers of patients gained weight in both groups, Chi square test has been applied. The term "statistically significant" applied to a p-value of equal or less than 0.05.
A total of 80 patient charts were reviewed during the mentioned period in this study. The demographic data of age and gender, baseline weight, doses of the antipsychotics and the data of after one month (30 ± 5 days) weight changes are shown in table 1. (Table1) shows that 3.96 kg gain occurred among those treated with Olanzapine, and 2.25 kg gain occurred among those treated with Risperidone, with P value of 0.12. Again (table1) reveals that Olanzapinetreated group gained about 6.11% of their baseline weight, while Risperidone-treated group gained about 2.98% of their baseline weight with P value of 0.03 which is statistically significant. (Table2) reveals the differences in the number of patients who gained weight between both genders in both treating groups. Among the 60 patients (27 male
RESULT:
and 33 female) who were treated with Olanzapine (mean of 10.91 milligrams daily), 42 patients (70%) {19 males (70.37%) and 23 females (69.69%)} gained variable amounts of weight during one month of therapy. Among the 20 patients (12 male and 8 female) who were treated with Risperidone (mean of 4.2 milligrams daily), 12 patients (60%) {6 males (50%) and 6 females (75%)} gained variable amounts of weight during one month of therapy. In an attempt to test any significant differences between the same gender of both groups, Chi square test applied, which returned back p-values of (0.2) for males, and (1) for females which are not significant. (Table3) analyzes the data of those who were treated with Olanzapine. Paired ttest used to test the weight differences before and one-month after therapy, which returned back to be not significant for the total sample (p value = 4.35), males (p value = 1.09), and females (p value = 6.8).
In order to make the picture more understandable, the mean amount of gains has been calculated (3.96 kg) with 95% confidence interval about the mean weight gain of 1.09 kg. Same analysis has been done for the percent of weight gain from the baseline weight, with mean of 6.21% of baseline weight and 95% confidence interval about the mean percent of 1.82%. These analyses concluded that for the 60 patients treated with 10.91 milligrams Olanzapine daily, 3.96 ± 1.09 kg (2.85 -5.05 kg) weight gain occurred, with 4.39% to 8.03% of baseline weight. Although females gained more weight, with more far away percent of baseline, the differences between females and males were assessed, by adopting unpaired t-test, and the p values were not significant (p value = 0.95 and p value = 0.33 respectively). (Table 4 ) analyzes the data of those who were treated with Risperidone. Paired ttest used to test the weight differences before and one-month after therapy, which returned back to be significant for the total sample (p value = 0.01), significant for female sample (p value = 0.01), and not significant for male sample (p value = 0.1). In order to make the picture more understandable, the mean amount of gains has been calculated (2.25 kg) with 95% confidence interval about the mean weight gain of 1.92 kg. Same analysis has been done for the percent of weight gain from the baseline weight, with mean of 2.89% of baseline weight and 95% confidence interval about the mean percent of 2.33%. These analyses concluded that for the 20 patients treated with 4.2 milligrams Risperidone daily, 2.25 ± 1.92 kg (0.33 -4.17 kg) weight gain occurred, with 0.56% to 5.22% of baseline weight. Although females gained more weight, with more far away percent of baseline, the differences between females and males were assessed, by adopting unpaired t-test, and the p values were not significant (p value = 0.63 and p value = 0.36 respectively). Table 2 : Gender differences of weight gained patients between Olanzapine-treated and Risperidone-treated groups. In the present study, charts of 80 patients have been reviewed for the evidences of weight gain after one month therapy with Olanzapine (60 patients) or risperidone (20 patients). Table 1 shows that weight gain occurs in both groups, but the amount of gain in Olanzapine-treated patients was higher (3.96 kg) than that of Risperidone (2.25 kg). Although the difference was not statistically significant (P = 0.12), but the amount of gain according to the baseline weight records was significantly higher in Olanzapine-treated group (6.21% of baseline weight) compared with the Risperidonetreated group (2.89% of baseline weight) with P value of 0.03. Such findings were relevant to other findings elsewhere 3, 22, 23 .
Allison et al (1999)
3 reported increases of 4.15 kg with Olanzapine and 2.1 kg with Risperidone during a 10 week period of therapy in some western countries. Also Basson et al (2001) 22 found significant differences in effect of weight change between Olanzapine and haloperidol but not between Olanzapine and Risperidone. Similarly, Kraus et al(1999) 23 observed a mean increase of 3.9kg during four weeks of treatment with Olanzapine. Although many explanations have been proposed for the possible association between the new antipsychotics usage and obesity worldwide, like histamine receptors antagonism 24 , serotonin receptors antagonism 24 , increased leptin secretion 23 , or sedation and subsequent lack of exercise; yet no clear mechanisms have been proposed to explain the increased potentials of Olanzapine over some other new antipsychotics in inducing weight gain. Table 2 reveals that males were more affected by the weight gain in Olanzapinetreated group (70.37% of males gained weight) though (69.69% of females gained DISCUSSION: weight), the picture was reversed among Risperidone-treated group, where females were more affected by the weight gain (75% of female gained weight , while 50% of males gained weight). In regard to the amount of weight gain in both genders, the current study revealed increased in weight in both genders in both groups. Although statistically not significant, but the study showed that females treated with Olanzapine gained more weight than males (4 kg and 6.98% of baseline weight in females versus 3.92 kg and 5.26% of baseline weight in males after one month) ( Table-3 ).
The picture was similar in Risperidonetreated group, where females gained 2.75 kg and 4.17% of baseline weight, whereas males gained 1.91 kg and 2.04% of baseline weight after one month of therapy (Table-4 ). Such variations between both genders, although were not significant, might be due to several factors, including predisposition for gaining weight, baseline weights of the patients, the dose of the antipsychotics, other demographic variables, co-morbid medical conditions, and even the underlying diagnoses, which call for further studies in future addressing such a concern.
Both second generation antipsychotics, Olanzapine and Risperidone, are associated with weight gain. However, Olanzapine appears to has a greater potential in inducing weight gain. Both genders affected nearly equally, though females were victims of more amount of weight gain. Limitations: the main limitation of the present study was the sample size differences of both group (60 Olanzapine-treated patients versus 20 Risperidone-treated patients). This limitation has been emerged because of more than one reason; including that the trend in Erbil city for the Antipsychotic prescrptions by psychiatrists is infavour of Olanzapine rather than Risperidone, which call for further studies for the reason behind such a trend. Furthermore, the study was retrospective one, and the author put certain inclusion criteria that fit only these 80 patients who were treated with these two Antipsychotics. Another limitation of the study is that the author only considered the weight change, However it would be more valuable if Body Mass Indecies were considered. This limitation merged out due to lack of data of patients lenghts in the patients files. This study calls for further, probably prospective, studies stressing on body mass indexies as well as other metabolic changes amongst those who receive Antipsychotics.
